EVH Stock Overview
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States.
Evolent Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$28.62|
|52 Week High||US$34.60|
|52 Week Low||US$18.33|
|1 Month Change||2.14%|
|3 Month Change||28.86%|
|1 Year Change||51.51%|
|3 Year Change||102.26%|
|5 Year Change||26.08%|
|Change since IPO||51.75%|
Recent News & Updates
Is Evolent Health (NYSE:EVH) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|EVH||US Healthcare Services||US Market|
Return vs Industry: EVH exceeded the US Healthcare Services industry which returned -38.1% over the past year.
Return vs Market: EVH exceeded the US Market which returned -12.3% over the past year.
|EVH Average Weekly Movement||6.2%|
|Healthcare Services Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: EVH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: EVH's weekly volatility (6%) has been stable over the past year.
About the Company
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
Evolent Health Fundamentals Summary
|EVH fundamental statistics|
Is EVH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EVH income statement (TTM)|
|Cost of Revenue||US$719.46m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.27|
|Net Profit Margin||-2.47%|
How did EVH perform over the long term?See historical performance and comparison
Is Evolent Health undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EVH ($28.62) is trading below our estimate of fair value ($67.84)
Significantly Below Fair Value: EVH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EVH is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Healthcare Services industry average.
PE vs Market: EVH is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVH is overvalued based on its Price-To-Book Ratio (4.3x) compared to the US Healthcare Services industry average (2.1x).
How is Evolent Health forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: EVH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EVH's is expected to become profitable in the next 3 years.
Revenue vs Market: EVH's revenue (15.7% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: EVH's revenue (15.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVH's Return on Equity is forecast to be low in 3 years time (6.3%).
How has Evolent Health performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVH is currently unprofitable.
Growing Profit Margin: EVH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVH is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare EVH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (9.5%).
Return on Equity
High ROE: EVH has a negative Return on Equity (-4%), as it is currently unprofitable.
How is Evolent Health's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: EVH's short term assets ($463.4M) exceed its short term liabilities ($382.5M).
Long Term Liabilities: EVH's short term assets ($463.4M) exceed its long term liabilities ($345.5M).
Debt to Equity History and Analysis
Debt Level: EVH's net debt to equity ratio (11.9%) is considered satisfactory.
Reducing Debt: EVH's debt to equity ratio has increased from 13.5% to 46.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EVH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EVH is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 4.9% per year.
What is Evolent Health current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EVH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Seth Blackley (42 yo)
Mr. Seth Barrie Blackley serves as Chief Executive Officer at Evolent Health, Inc. since October 1, 2020. He serves as President of True Health Indiana, Inc. (True Health Indiana). Mr. Blackley co-founded...
CEO Compensation Analysis
Compensation vs Market: Seth's total compensation ($USD6.53M) is about average for companies of similar size in the US market ($USD6.83M).
Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.
Experienced Management: EVH's management team is considered experienced (3.1 years average tenure).
Experienced Board: EVH's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.
Evolent Health, Inc.'s employee growth, exchange listings and data sources
- Name: Evolent Health, Inc.
- Ticker: EVH
- Exchange: NYSE
- Founded: 2011
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$2.621b
- Shares outstanding: 91.59m
- Website: https://www.evolenthealth.com
Number of Employees
- Evolent Health, Inc.
- 800 North Glebe Road
- Suite 500
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.